初次诊断时晚期梅克尔细胞癌相关因素及放射治疗使用情况:来自美国国家癌症数据库的结果
基于美国国家癌症数据库2004至2013年11917例梅克尔细胞癌患者的横断面回顾性分析,评估初次诊断时晚期疾病及放射治疗使用的相关因素。非裔美国人种、无医疗保险、Charlson-Deyo合并症评分至少1分、居住地距治疗机构超过26英里、肿瘤位于下肢/髋部或躯干、低分化或未分化组织学与晚期诊断相关;印第安人种、肿瘤大小1.5至2.7厘米、选择不手术、术后切缘阳性及在综合癌症项目机构治疗与放射治疗使用相关。
要点
- 非裔美国人种、无医疗保险、合并症评分至少1分与初次诊断时晚期梅克尔细胞癌相关。
- 肿瘤位于下肢/髋部或躯干、低分化或未分化组织学与晚期诊断相关。
- 放射治疗使用与印第安人种、肿瘤大小1.5至2.7厘米、选择不手术、术后切缘阳性及综合癌症项目机构治疗相关。
核心结论
- 多种因素与初次诊断时晚期梅克尔细胞癌及放射治疗使用相关,医疗保健模式应考虑这些因素,并应努力改善可改变的因素。
研究设计与样本
- 横断面回顾性分析,纳入美国国家癌症数据库2004至2013年注册的梅克尔细胞癌患者,共识别11917例患者,分期分析和放射治疗分析分别排除3152例和4586例因数据缺失的患者。
主要发现
- 非裔美国人种与非裔美国人种相比(OR 1.49,95%CI 1.06-2.10,P=0.023)、无医疗保险(OR 2.15,95%CI 1.40-3.30,P<0.001)、Charlson-Deyo合并症评分至少1分(OR 1.21,95%CI 1.09-1.34,P<0.001)与初次诊断时晚期梅克尔细胞癌相关。
- 居住地距治疗机构超过26英里(OR 1.18,95%CI 1.03-1.35,P=0.015)、肿瘤位于下肢/髋部(OR 1.59,95%CI 1.42-1.78,P<0.001)或躯干(OR 2.05,95%CI 1.81-2.33,P<0.001)、低分化(OR 2.57,95%CI 1.13-5.82,P=0.024)或未分化(OR 3.11,95%CI 1.36-7.15,P=0.007)肿瘤组织学与初次诊断时晚期梅克尔细胞癌相关。
- 放射治疗使用与印第安人种(OR 5.04,95%CI 1.10-22.99,P=0.037)、肿瘤大小1.5至2.7厘米(OR 1.27,95%CI 1.10-1.47,P=0.001)、选择不手术(OR 2.77,95%CI 1.90-4.03,P<0.001)、术后切缘阳性(OR 1.39,95%CI 1.18-1.63,P<0.001)及在综合癌症项目机构接受治疗(OR 1.25,95%CI 1.03-1.50,P=0.020)相关。
临床怎么用
- 作者认为医疗保健模式应考虑这些因素,并应努力改善可改变的因素。
局限性
- 回顾性设计限制了结果的普适性。
- 所使用放射治疗方案的精确细节不可获得。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The stage of disease at initial diagnosis and the use of radiation therapy (RT) are important determinants of survival in patients with Merkel cell carcinoma (MCC). OBJECTIVE: To define factors that are associated with advanced-stage MCC at the time of initial diagnosis and the use of RT. METHODS: Cross-sectional, retrospective analysis of patients with MCC registered in the National Cancer Database during the period from 2004 to 2013. RESULTS: A total of 11,917 patients were identified; 3152 and 4586 patients were excluded from the staging and RT analyses, respectively, because of lack of available data. African American ethnicity (odds ratio [OR], 1.49; 95% confidence interval [CI], 1.06-2.10; P = .023), lack of medical insurance (OR, 2.15; 95% CI, 1.40-3.30; P < .001), Charlson-Deyo comorbidity score of at least 1 (OR, 1.21; 95% CI, 1.09-1.34; P < .001), residence more than 26 miles from a treatment facility (OR, 1.18; 95% CI, 1.03-1.35; P = .015), tumor located on the lower limb/hip (OR, 1.59; 95% CI, 1.42-1.78; P < .001) or trunk (OR, 2.05; 95% CI, 1.81-2.33; P < .001), and poorly (OR, 2.57; 95% CI, 1.13-5.82; P = .024) or undifferentiated (OR, 3.11; 95% CI, 1.36-7.15; P = .007) tumor histology predicted advanced-stage MCC at the time of initial diagnosis. The use of RT was associated with Native American ethnicity (OR, 5.04; 95% CI, 1.10-22.99; P = .037), tumor size between 1.5 and 2.7 cm (OR, 1.27; 95% CI, 1.10-1.47; P = .001), electing not to have surgery (OR, 2.77; 95% CI, 1.90-4.03; P < .001), positive postsurgical margins (OR, 1.39; 95% CI, 1.18-1.63; P < .001), and receiving treatment at a comprehensive cancer program (OR, 1.25; 95% CI, 1.03-1.50; P = .020). LIMITATIONS: Retrospective design limits generalizability of the results, and precise details of RT regimens utilized were not available. CONCLUSIONS: A number of factors are associated with advanced-stage MCC at initial diagnosis and the use of RT. Health care models should account for these factors, and efforts should be directed toward improving those that are modifiable.
引用
- Trofymenko O, Zeitouni NC, Kurtzman DJB, et al. Factors associated with advanced-stage Merkel cell carcinoma at initial diagnosis and the use of radiation therapy: Results from the National Cancer Database. J Am Acad Dermatol. 2018. PMID: 29574087. doi:10.1016/j.jaad.2018.03.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。